Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
Opinion
Video
Mitigating Alternative Topical Treatments: Ruxolitinib's Role in Atopic Dermatitis Management
Author(s):
A dermatology expert reviews findings from a recently presented study on using other atopic dermatitis (AD) treatments within six months of initiating ruxolitinib cream. The expert assesses ruxolitinib's effectiveness and potential role in treatment, highlighting the need for further research on its long-term implications in AD management.
Video content above is prompted by the following questions:
- How do the observed reductions in other atopic dermatitis treatments, both topical and oral, within six months of initiating ruxolitinib cream impact your perception of its effectiveness and potential role in treatment strategies?
- What further research or clinical investigations would you propose to better understand the long-term effects and implications of initiating ruxolitinib cream on atopic dermatitis management and patient outcomes?
Related Videos
Related Content
